These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. Raheem F; Alsuhebany N; Hickey Zacholski E; Paulic N; Sandler A; Uk N; Moore DC Expert Opin Drug Saf; 2023; 22(10):921-928. PubMed ID: 37612255 [TBL] [Abstract][Full Text] [Related]
4. Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials. Eaton JS; Miller PE; Mannis MJ; Murphy CJ J Ocul Pharmacol Ther; 2015 Dec; 31(10):589-604. PubMed ID: 26539624 [TBL] [Abstract][Full Text] [Related]
5. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591 [TBL] [Abstract][Full Text] [Related]
6. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. Zhu Y; Liu K; Wang K; Zhu H Cancer; 2023 Jan; 129(2):283-295. PubMed ID: 36408673 [TBL] [Abstract][Full Text] [Related]
7. Risk Minimization of Antibody-Drug Conjugates in Oncology: A Review. Lievano FA; Scarazzini LJ; Tyczynski JE; Schubert CM; Renz CL Drug Saf; 2021 Jul; 44(7):733-742. PubMed ID: 33988833 [TBL] [Abstract][Full Text] [Related]
8. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications. Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416 [TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates for Breast Cancer. Marmé F Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488 [TBL] [Abstract][Full Text] [Related]
10. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Campos MP; Konecny GE Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302 [TBL] [Abstract][Full Text] [Related]
11. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Ferraro E; Drago JZ; Modi S Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530 [TBL] [Abstract][Full Text] [Related]
12. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Tarantino P; Ricciuti B; Pradhan SM; Tolaney SM Nat Rev Clin Oncol; 2023 Aug; 20(8):558-576. PubMed ID: 37296177 [TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates as a Targeted Therapeutic Approach Across Entities in Oncology. Lordick F; Merz M; Büch E; Aigner A Dtsch Arztebl Int; 2023 May; 120(19):329-336. PubMed ID: 37073718 [TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. Vezina HE; Cotreau M; Han TH; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650 [TBL] [Abstract][Full Text] [Related]
19. Picking the optimal target for antibody-drug conjugates. Mathur R; Weiner GJ Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470 [TBL] [Abstract][Full Text] [Related]
20. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)]. ; ; ; Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):741-762. PubMed ID: 37460440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]